Arcellx (ACLX) Cash from Investing Activities (2021 - 2025)
Arcellx's quarterly Cash from Investing Activities came in at $57.8 million in Q4 2025, up 1502.86% year-on-year from $3.6 million in Q4 2024, and up 388.61% quarter-over-quarter from -$20.0 million in Q3 2025.
Arcellx has reported Cash from Investing Activities for 5 years, with the latest figure at $57.8 million in Q4 2025.
- For the quarter ending Q4 2025, Cash from Investing Activities rose 1502.86% year-over-year to $57.8 million; the trailing twelve-month figure through Dec 2025 stood at $86.3 million (up 147.15% YoY), and the FY2025 full-year result was $86.3 million, up 147.15% from the prior year.
- Cash from Investing Activities for Q4 2025 stood at $57.8 million, up from -$20.0 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $57.8 million in Q4 2025, with the low at -$206.8 million in Q1 2024.
- Average Cash from Investing Activities over 5 years is -$22.4 million, with a median of -$6.0 million recorded in 2024.
- Year-over-year, Cash from Investing Activities sank 32807.22% in 2022 and surged 1502.86% in 2025.
- Tracing ACLX's Cash from Investing Activities over 5 years: stood at -$17.7 million in 2021, then surged by 290.35% to $33.6 million in 2022, then tumbled by 37.49% to $21.0 million in 2023, then plunged by 119.6% to -$4.1 million in 2024, then soared by 1502.86% to $57.8 million in 2025.
- The last three Cash from Investing Activities figures came in at $57.8 million (Q4 2025), -$20.0 million (Q3 2025), and $10.7 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.89 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 638.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -431.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -428.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 57.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 57.80 Mn |
| Dec 31, 2025 | 57.80 Mn |
| Sep 30, 2025 | -20.03 Mn |
| Sep 30, 2025 | -20.03 Mn |
| Jun 30, 2025 | 10.74 Mn |
| Jun 30, 2025 | 10.74 Mn |
| Mar 31, 2025 | 37.78 Mn |
| Mar 31, 2025 | 37.78 Mn |
| Dec 31, 2024 | -4.12 Mn |
| Dec 31, 2024 | -4.12 Mn |
| Sep 30, 2024 | 35.76 Mn |
| Sep 30, 2024 | 35.76 Mn |
| Jun 30, 2024 | -7.87 Mn |
| Jun 30, 2024 | -7.87 Mn |
| Mar 31, 2024 | -206.81 Mn |
| Mar 31, 2024 | -206.81 Mn |
| Dec 31, 2023 | 21.02 Mn |
| Dec 31, 2023 | 21.02 Mn |
| Sep 30, 2023 | -160.03 Mn |
| Sep 30, 2023 | -160.03 Mn |
| Jun 30, 2023 | 51.27 Mn |
| Jun 30, 2023 | 51.27 Mn |
| Mar 31, 2023 | -66.77 Mn |
| Mar 31, 2023 | -66.77 Mn |
| Dec 31, 2022 | 33.62 Mn |
| Dec 31, 2022 | 33.62 Mn |
| Sep 30, 2022 | -81.42 Mn |
| Sep 30, 2022 | -81.42 Mn |
| Jun 30, 2022 | -59.23 Mn |
| Jun 30, 2022 | -59.23 Mn |
| Mar 31, 2022 | -10.64 Mn |
| Mar 31, 2022 | -10.64 Mn |
| Dec 31, 2021 | -17.66 Mn |
| Dec 31, 2021 | -17.66 Mn |
| Sep 30, 2021 | -61.07 Mn |
| Sep 30, 2021 | -61.07 Mn |
| Jun 30, 2021 | -180,000.00 |
| Jun 30, 2021 | -180,000.00 |
| Mar 31, 2021 | -1.07 Mn |
| Mar 31, 2021 | -1.07 Mn |